Clinical Observation on Chaihu Shugansan Combined with Xuanfu Daizhetang in Treating Barrett's Esophagus with Liver-stomach Disharmony
10.13422/j.cnki.syfjx.20241122
- VernacularTitle:柴胡疏肝散合旋覆代赭汤治疗肝胃不和型Barrett食管的临床观察
- Author:
Xiao WANG
1
;
Xiaosu WANG
1
;
Bingduo ZHOU
1
;
Guangsu XIONG
2
;
Qi YU
1
;
Ji SUN
1
;
Yun ZHOU
1
;
Yi JING
3
;
Shengliang ZHU
1
;
Li LI
4
Author Information
1. Yueyang Hospital of Integrated Traditional Chinese and Western Medicine， Shanghai University of Traditional Chinese Medicine（TCM）， Shanghai 200437， China
2. Tongji Hospital of Tongji University， Shanghai 200092， China
3. Sichuan North Road Community Health Service Centre of Hongkou District， Shanghai 200080， China
4. Guanghua Hospital Affiliated to Shanghai University of TCM， Shanghai 200052， China
- Publication Type:Journal Article
- Keywords:
Chaihu Shugansan;
Xuanfu Daizhetang;
liver-stomach disharmony;
Barrett's esophagus;
clinical efficacy;
bile acids
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2024;30(24):10-17
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo observe the clinical efficacy and safety of Chaihu Shugansan combined with Xuanfu Daizhetang （CHSG-XFDZ） in the management of Barrett's esophagus （BE） with liver-stomach disharmony. MethodA randomized， parallel， controlled， double-blind clinical trial was conducted. BE patients who met the inclusion criteria were randomized into an observation group and a control group， with 34 patients in each group. The observation group was treated with CHSG-XFDZ combined with omeprazole capsules， and the control group was treated with CHSG-XFDZ mimetic combined with omeprazole capsules. Both groups were treated for 12 weeks. The traditional Chinese medicine （TCM） symptom scores， response rate， BE lesion area， BE pathological changes， and bile acid profile were taken as the indicators to jointly evaluate the clinical efficacy and safety of the two groups. ResultA total of 62 patients who completed the trial were included for statistical analysis， including 32 in the observation group and 30 in the control group. There were no statistically significant differences in baseline demographics or disease characteristics between two groups， which suggested that the two groups were comparable. The total response rate in the observation group was 93.7% （30/32）， which was higher than that （60.0%， 18/30） in the control group （χ2=24.766， P<0.05）. After treatment， the response rate regarding the pathological changes in the observation group was 62.5% （20/32）， which was higher than that （23.3%， 7/30） in the control group （χ2=10.270， P<0.05）. The response rate regarding the BE lesion area change in the observation group was 21.9% （7/32）， which had no statistically significant difference from that （6.7%， 2/30） in the control group， which indicated that the advantages of the two regimens were not obvious in terms of reducing the area of BE lesions. Compared with the control group after treatment， the observation group regulated the bile acid profile， which pointed out the direction for further exploring the mechanism of CHSG-XFDZ in treating BE. Neither group showcased adverse reactions with clinical significance during the treatment period. ConclusionCHSG-XFDZ outperformed the control group in terms of alleviating TCM symptoms， ameliorating pathological changes， and improving the bile acid profile in the BE patients with liver-stomach disharmony. It demonstrates certain potential in reducing the lesion area. This formula is safe and effective in treating BE patients with liver-stomach disharmony and deserves further clinical research and widespread application.
